Biophan-Europe Wins Scientific Award for Research Presentation from Leading European Society on MRI Technology; Honor Spotlights Company's Innovations to Enhance MRI Visualization and Enable Improved MRI-Guided Interventional Procedures.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH) (Frankfurt/FSE: BTN), a developer of next-generation biomedical technology, announced today that a research scientist based at its Biophan-Europe division has won an important scientific award for his presentation of novel medical device technologies for improved Magnetic Resonance Imaging (MRI) capabilities. The award recognized Biophan-Europe's presentation at the prestigious 26th Annual Scientific Meeting of the European Society for Magnetic Resonance in Medicine and Biology last week in Basel, Switzerland.

The Cum Laude EPOS Award, one of only eight given in a candidate pool of 520, was bestowed on Erwin Immel, Dipl.-Ing., a Research Engineer with Biophan-Europe and the University of Applied Sciences, Gelsenkirchen, Germany. The Cum Laude EPOS Award titled "Resonant circuits for inductively coupled visualisation of a self expanding stent based porcine heart valve", spotlights Biophan-Europe's research to develop methods to enable effective and clear MRI imaging of vascular implants through the use of the Company's proprietary resonant circuit technology. The Company's active-MRI technology for the imaging of stents and vena cava filters has demonstrated excellent feasibility in preclinical animal studies.

Biophan-Europe's conference presentation highlighted key results and potential implications of its research. These include enabling MRI imaging of heart valve prosthesis to provide doctors a more effective and less invasive alternative to diagnose heart valve function compared to the currently available invasive techniques, as well as the ability to enable a new generation of MRI-guided implantable stent-based heart valves.

Stents are small implantable devices commonly used to prop open arteries to maintain healthy blood flow in cardiac patients. The Company's technology could also be used to enable MRI visualization of stent interiors to diagnose thrombi (blood clots) and tissue growth inside the stents (restenosis) as well as to enable MRI guided implantation. The presentation highlighted the technology's potential to develop MRI-guided percutaneous, minimally invasive implantation of heart valves, according to Biophan-Europe President and CEO, Dr. Michael Friebe.

"Biophan-Europe is truly delighted to win this award from our colleagues in the European scientific community," Dr. Friebe said. "The award recognizes the importance of MRI visualization capabilities for almost a million patients worldwide requiring repair of heart valves."

Biophan-Europe CTO Professor Andreas Melzer added, "We intend to continue to develop innovative solutions in the emerging field of diagnostic and interventional MRI in order to open new possibilities in minimally invasive surgery and interventions without X-ray burden or iodine contrast agents."

Biophan-Europe, based in Germany, is developing a wide range of novel solutions that make implantable medical devices, such as stents, vena cava filters and heart valves, clearly imageable under MRI.

For more information about the European Society for Magnetic Resonance in Medicine and Biology, please visit http://www.esmrmb.org.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 41 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also traded on the Frankfurt Stock Exchange under the ticker symbol BTN. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.